The presentation marks the third consecutive year that LEO Pharma has presented late-breaking data at AAD. Alongside this presentation, new systemic exposure data has also been shared for ...

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

(PRNewsfoto/Sun Pharmaceutical Industries Inc., USA (Sun Pharma)) Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumor cancers.

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...

“Ireland has our pharma companies,” said US president Donald Trump on Wednesday in some of the most significant comments of his encounter with Taoiseach Micheál Martin. And he wants them bac ...

In his March 17 op-ed, “We should stop acting as if Big Pharma is the big villain in American health care,” Erick Erickson writes, “The government cannot provide clarity or direction for ...

My wife and I would both be dead, but for what many derisively call “Big Pharma.” My wife has a rare, genetic form of stage four lung cancer for which there is no cure. Her lungs are filled ...

You might misinterpret the signals someone is sending today as bold Mars in your subconscious zone connects with buttoned-up Saturn in your sharing sector. Maybe you’ll lean in for an air kiss ...

Hampton was appointed by the Justice Department in 2019 to represent the financial interests of victims in the Purdue Pharma bankruptcy case. For two years, he served on a committee of creditors.

Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid settlement of at least $7.4 billion after a setback in the U.S. Supreme Court last year.

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations. Last year, it signed ...